Investigation of 5-fluorouracil cardiotoxicity in combinational therapy: Influence of risk factors and demographics in a Pakistani population
Open Access
- 3 October 2024
- journal article
- research article
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 31 (7) , 1037-1045
Abstract
Introduction: 5-Fluorouracil (5-FU) is a chemotherapeutic agent used to treat various types of cancers. Although widely used, it has consistently been attributed to cardiotoxicities after administration. The purpose of this study was to assess the parameters and predictors of cardiotoxicities associated with various 5-FU-based chemotherapeutic protocols in patients with GI/colorectal cancer, as well as the correlation of these cardiotoxic events with age, sex, cumulative dose, and risk factors such as obesity, hypertension, and family history of cardiac diseases. Methods: A prospective study consisting of 396 patients of both sexes was conducted in the oncology ward of Nishtar Hospital in Multan, Pakistan. Patients were grouped according to the therapeutic protocol they received (5-FU monotherapy or in combination, with different dosing regimens). Electrocardiography and serum troponin levels were used to assess 5-FU-induced cardiotoxicity. In cases where cardiotoxicity was detected, 5-FU treatment was interrupted; nitroglycerin, nitrates, and calcium channel blockers were administered; and cardiac monitoring was initiated. 5-FU was discontinued in all cases of acute myocardial infarction. Results: Of the 396 patients, 28.5% reported different cardiotoxic symptoms after receiving various 5-FU-containing protocols. 35% had anginal pain, 13% suffered a myocardial infarction, 11% developed hypertension, and 10% presented heart failure. Patients receiving 5-FU combination therapy showed cardiotoxic events that were significantly different from those on 5-FU monotherapy. Based on the ECG results, only the QTc-d interval increased significantly (p < 0.001) after therapy. 68% of the patients had troponin levels > 2 ng/mL at the end of treatment. Conclusions: Pre-existing cardiac diseases, treatment duration, smoking, and obesity were found to be influential components in the development of cardiotoxicity, and patients with cancer should be closely monitored during 5-FU chemotherapy.Keywords
This publication has 33 references indexed in Scilit:
- The Incidence, Risk Factors, and Outcomes With 5-Fluorouracil–Associated Coronary VasospasmJACC: Cardiooncology, 2021
- Cardiotoxicities of 5-Fluorouracil and Other FluoropyrimidinesCurrent Treatment Options in Oncology, 2020
- Vascular Complications of Cancer ChemotherapyCanadian Journal of Cardiology, 2016
- Alternative Treatment Options in Colorectal Cancer Patients With 5–Fluorouracil- or Capecitabine-Induced CardiotoxicityClinical Colorectal Cancer, 2013
- Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective studyJournal of Cancer Research and Clinical Oncology, 2007
- 5-Fluorouracil and dihydropyrimidine dehydrogenaseInternational Journal of Clinical Oncology, 2003
- Symptomatic Cardiotoxicity Associated with 5‐FluorouracilPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1997
- The Therapeutic Impact of Dipyridamole: Chemopotentiation of the Cytotoxic Combination 5-Fluorouracil/Cisplatin in an Animal Model of Human Bladder CancerJournal of Urology, 1991
- Nonlinear pharmacokinetic characteristics of 5-fluorouracil (5-FU) in colorectal cancer patientsEuropean Journal of Clinical Pharmacology, 1987
- Nonlinear pharmacokinetic models for 5-fluorouracil in man: Intravenous and intraperitoneal routesClinical Pharmacology & Therapeutics, 1980